Abstract
Development of a second malignant neoplasm (SMN) following prolonged cytotoxic therapy is a potential delayed consequence of tumor treatment [1, 5, 6, 20, 26, 27, 31, 34, 46, 48, 49, 51]. In addition, specified primary neoplasms are associated with the development of other primary malignancies through either a common etiology or an impaired patient’s defense mechanism [44]. The oncogenic potential of adjuvant chemotherapy in early breast cancer may, therefore, best be analyzed by looking at the occurrence of SMNs in prospective randomized trials using a similar, nontreated patient population (surgical control). This report summarizes the frequency of SMNs in five controlled adjuvant chemotherapy trials and two studies with no surgical control group.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Boice JD Jr, Grenne MH, Killen JY Jr, Eilenberg SS, Keehn RJ, McFadden E, Chen TT, Fraumeni JF Jr (1983) Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 309: 1079–1084
Bonadonna G, Valagussa P (1981) Dose-reponse effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15
Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 297: 405–410
Busk T, Clemmensen J (1947) The frequency of left-and right-sided breast carcinoma. Br J Cancer 1: 345–351
Carey RW, Holland JF, Sheehe PR, Graham S (1967) Association of cancer of the breast and acute myelocytic leukemia. Cancer 20: 1080–1088
Chan PYM, Sadoff L, Winkley JH (1977) Second malignancies following first breast cancer in prolonged thiotepa adjuvant chemotherapy. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer. Elsevier/North-Holland Biomedical, Amsterdam, pp 597–607
Crowther D (1979) Controlled adjuvant chemotherapy trials for breast cancer in the United Kingdom. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer, vol II. Grune and Stratton, New York, pp 237–244
Curtis RE, Hankey BF, Myers MH, Young JL (1984) Risk of leukemia associated with the first course of cancer treatment: an analysis of the surveillance, epidemiology and end results program experience. JNCI 72: 531–544
Davis HL Jr, Prout MN, McKenna PJ, Cole DR, Korbitz BC (1973) Acute leukemia complicating metastatic breast cancer. Cancer 31: 543–546
Desaive P (1949) Le cancer mammaire bilatéral. J Radiol [D] 30: 335–338
Devitt EF (1971) Bilateral mammary cancer. Ann Surg 174: 774–778
Durkee C, Benson R (1980) Bladder cancer following administration of cyclophosphamide. Urology 16: 145–148
Ershler WB, Robins HI, Davis HL (1982) Emergence of acute non-lymphocytic leukemia in breast cancer patients. Am J Med Sci 284: 23–31
Fairchild WV, Spence CR, Solomon HD, Gangai MP (1979) The incidence of bladder cancer after cyclophosphamide therapy. J Urol 122: n 163–164
Farrow DH (1969) Bilateral mammary cancer. Cancer 9: 1182–1188
Foucar K, McKenna RW, Bloomfield CD, Bowers TK, Brunning RD (1979) Therapy-related leukemia: A panmyelosis. Cancer 43: 1285–1296
Haagensen CD, Lance N, Lattes R, Bodian C (1978) Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 42: 737–769
Harnett W (1948) A statistical report on 2,529 cases of cancer of the breast. Br J Cancer 2: 212–238
Harrington SW (1946) Survival rates of radical mastectomy for unilateral and bilateral carcinoma of the breast. Surgery 19: 154–166
Harris CC (1976) The carcinogenicity of anticancer drugs: a hazard in man. Cancer 37: 1014–1024
Hawkins JW (1944) Evaluation of breast cancer therapy as a guide to control programs. J Natl Cancer Inst 4: 445–460
Herrman JB (1955) Bilateral mammary carcinoma. Acta UICC II: 433–439
Holdener EE, Osterwalder J, Senn HJ, Enderlin F, Gloor F (1982) Zweitmalignome bei operiertem Mammakarzinom. Schweiz Med Wochenschr 112: 1800–1804
Hubbard TB, Montgomery MD (1953) Nonsimultenaous bilateral carcinoma of the breast. Surgery 34: 706–723
Jones SE, Salmon SE, Allen H, Giordano GF, Davis S, Chase E, Moon TE, Hensinkveld RS (1982) Adjuvant treatment of node-positive breast cancer with adriamycin-cyclophosphamide with or without radiation therapy: interim results of an ongoing clinical trial. Recent Results Cancer Res 80: 162–169
Karchmer RK, Amare M, Larsen WE, Mallouk AG, Caldwell GG (1974) Alkylating agents as leukomogens in multiple myeloma. Cancer 33: 1103–1107
Kardinal CG, Donegan WL (1980) Second cancers after prolonged adjuvant thiotepa for operable carcinoma of the breast. Cancer 45: 2042–2046
Kesseler HJ, Grier RN, Seidmann I, Mcllveen SJ (1970) Bilateral primary breast cancer. JAMA 236: 278–280
Kilgore AR, Bell HG, Ahlquist RE (1956) Cancer in the second breast. Am J Surg 92: 156–161
Koyama H, Wada T, Takahashi Y, Nishizawa Y, Iwanaga T, Aoki Y, Terasawa T, Kosaki G, Kajita A, Wada A (1980) Surgical adjuvant chemotherapy with mitomycin C and cyclophosphamide in Japanese patients with breast cancer. Cancer 46: 2373–2379
Kyle RA, Pierre RV, Bayrd ED (1975) Multiple myeloma and acute leukemia associated with alkalyting agents. Arch Intern Med 135: 185–192
Lapis K, Kis A (1956) Über beiderseitige Brustkrebse. Zentralbl Chir 81: 680–689
Leis HP Jr, Mersheimer WL, Black MM, Chabon A (1965) The second breast. NY State J Med 65: 2460–2468
Lerner HJ (1978) Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. Cancer Treat Rep 62: 1135–1138
Lewis D, Rienhoff WF Jr (1932) A study of the results of operations for the cure of cancer of the breast. Ann Surg 95: 336–409
Lewison EF, Neto AS (1971) Bilateral breast cancer at the Johns Hopkins Hospital. A discussion of the dilemma of contralateral breast cancer. Cancer 28: 1297–1301
Marquardt H (1977) Induction of malignant transformation and mutagenesis in cell cultures by cancer chemotherapeutic agents. Cancer 40: 1930–1934
Martynjuk UU, Kalinikna VI (1968) Cancer of the second breast. Vopr Onkol 14: 92–95
McWilliams CA (1925) Bilateral mammary cancer operations. Ann Surg 82: 63–80
Medina D (1977) Enhancement of mammary tumor formation in mice by a cytostatic drug, melphalan. Cancer Res 37: 317–319
Moertel CG, Soule EH (1957) The problem of the second breast: A study of 118 patients with bilateral carcinoma of the breast. Ann Surg 146: 764–771
Nissen-Meyer R, Kjellgren K, Malmio K, Mansson B, Norin T (1978) Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41: 2088–2098
Nowell P, Glick JH, Bucolo A, Finan J, Creech R (1981) Cytogenic studies of bone marrow in breast cancer patients after adjuvant chemotherapy. Cancer 48: 667–673
Penn I (1981) Depressed immunity and the development of cancer. Clin Exp Immunol 46: 459–474
Penn I (1982) Second neoplasms following radiotherapy of chemotherapy for cancer. Am J Clin Oncol 5: 83–96
Portugal MA, Falkson HC, Stevens K, Falkson G (1979) Acute leukemia as a complication of long-term treatment of advanced breast cancer. Cancer Treat Rep 63: 177–181
Robins HI, Ershler WB, Hafez GR, Dohlberg S, Arndt C (1980) Acute nonlymphocytic leukemia in breast cancer: Therapy related or de novo? Lancet I: 91–92
Rosner F, Carey RW, Zarrabi MH (1978) Breast cancer and acute leukemia: report of 24 cases and review of the literature. Am J Hematol 4: 151–172
Schmähl D, Habs M, Lorenz M, Wagner I (1982) Occurrence of second tumors in man after anticancer drug treatment. Cancer Treat Rev 9: 167–194
Senn HJ, Jungi WF, Amgwerd R (1979) Divergent effect of chemoimmunotherapy with LMF/BCG in node-negative and node-positive breast cancer. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer, vol II. Grune and Stratton, New York, pp 245–252
Sieber SM (1975) Cancer chemotherapeutic agents and carcinogenesis. Cancer Chemother Rep 59: 915–918
Slack NH, Bross IDJ, Nemoto T, Fisher B (1973) Experiences with bilateral primary carcinoma of the breast. Surg Gynecol Obstet 136: 433–440
Smithers DW, Rigby-Jones P, Gatton DAG, Payne PM (1952) Cancer of the breast. A review. Br J Radiol [Suppl 4]
Strauss BS (1977) Molecular biology of the response of cells to radiation and to radiomimetic chemicals. Cancer 40: 471–480
Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U (1983) Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1: 2–10
Webber BL, Heise H, Neifeld JP, Costa J (1981) Risk of subsequent contralateral breast carcinoma in a population of patients with in-situ breast carcinoma. Cancer 47: 2928–2932
Weisburger EK (1977) Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents. Cancer 40: 1935–1949
Weisburger JH, Griswold DP Jr, Prejean JD, Casey AE, Wood HB, Weisburger EK (1975) The carcinogenic properties of some of the principal drugs used in clinical cancer chemotherapy. Recent Results Cancer Res 52: 1–17
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Holdener, E.E. et al. (1984). Second Malignant Neoplasms in Operable Carcinoma of the Breast. In: Senn, HJ. (eds) Adjuvant Chemotherapy of Breast Cancer. Recent Results in Cancer Research, vol 96. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82357-2_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-82357-2_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82359-6
Online ISBN: 978-3-642-82357-2
eBook Packages: Springer Book Archive